EGFR and lung carcinoma: More recently, according to the Annual quality reports for lung cancer in Norway, testing rate for EGFR mutations was 74.8% in 2017, 84.6% in 2018, 84.2% in 2019, and 84.4% in 2020 (7, 8, 17, 18).